Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer

James, Nicholas D.; Hussain, Syed A.; Jenkins, Peter; Tremlett, Jean; Rawlings, C.; Crundwell, Malcolm; Sizer, Bruce; Sreenivasan, Thiagarajan; Hendron, Carey; Lewis, Rebecca; Waters, Rachel; Huddart, Robert

doi:10.1056/nejmoa1106106

Cited by 812 publications

(690 citation statements)

References 18 publications

Supporting

Mentioning

614

Contrasting

Unclassified

Order By: Relevance

“…62,63 In a randomized trial of 360 patients, RT with concurrent mitomycin C and 5-FU improved the 2-year locoregional DFS rate from 54% (RT alone) to 67% (P=.01), and 5-year OS rate from 35% to 48% (P=.16), without increasing grade 3/4 acute or late toxicity. 63 Hence, RT alone is only indicated for those who cannot tolerate a cystectomy or chemotherapy because of medical comorbidities.…”

Section: Rt Following Turbt As Primary Treatment For Mibcmentioning

confidence: 99%

“…RT with concurrent cisplatin-based chemotherapy or 5-FU plus mitomycin as a radiosensitizer is the most common and well-studied chemoRT method used to treat MIBC. [50][51][52][53][54]62,63,65 The following radiosensitizing regimens are recommended: cisplatin plus 5-FU; cisplatin plus paclitaxel; and 5-FU plus mitomycin C. Doublet chemotherapy is generally preferred. Cisplatin alone or low-dose gemcitabine (category 2B) may be considered as alternative regimens.…”

Section: Treatment Of T2 T3 and T4a Tumorsmentioning

confidence: 99%

See 1 more Smart Citation

Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

Spiess¹,

Agarwal²,

Bangs³

et al. 2017

J Natl Compr Canc Netw

228

173

View full text Add to dashboard Cite

OverviewAn estimated 79,030 new cases of urinary bladder cancer (60,490 men and 18,540 women) will be diagnosed in the United States in 2017 and approximately 16,870 deaths (12,240 men and 4630 women) will occur. Please NoteThe NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines Disclosures for the NCCN Bladder Cancer PanelAt the beginning of each NCCN Guidelines panel meeting, panel members review all potential conflicts of interest. NCCN, in keeping with its commitment to public transparency, publishes these disclosures for panel members, staff, and NCCN itself.Individual disclosures for the NCCN Bladder Cancer Panel members can be found on page 1267 (The most recent version of these guidelines and accompanying disclosures are available on the NCCN Web site at NCCN.org.)These guidelines are also available on the Internet. For the latest update, visit NCCN.org.

show abstract

Section: Rt Following Turbt As Primary Treatment For Mibcmentioning

confidence: 99%

Section: Treatment Of T2 T3 and T4a Tumorsmentioning

confidence: 99%

Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

Spiess¹,

Agarwal²,

Bangs³

et al. 2017

J Natl Compr Canc Netw

228

173

View full text Add to dashboard Cite

show abstract

“…majority of survival rate advantage in the randomised control trial setting (29,30). This has resulted in the ever apparent requirement for bladder reconstruction.…”

Section: Surgicalmentioning

confidence: 99%

Bladder reconstruction: The past, present and future

2015

Self Cite

View full text Add to dashboard Cite

Abstract. Ileal conduit urinary diversion is the gold standard treatment for urinary tract reconstruction following cystectomy. This procedure uses gastrointestinal segments for bladder augmentation, a technique that is often associated with significant complications. The substantial progression in the fields of tissue engineering and regenerative medicine over the previous two decades has resulted in the development of techniques that may lead to the construction of functional de novo urinary bladder substitutes. The present review identifies and discusses the complications associated with current treatment options post-cystectomy. The current techniques, achievements and perspectives of the use of biomaterials and stem cells in the field of urinary bladder reconstruction are also reviewed.

show abstract

“…Recent radiotherapy studies, evaluating concurrent regimes with radio-sensitizers, such as chemotherapy or carbogen and nicotinamide, have seen survival outcomes improve and equal results from contemporary surgical series [7,8]. Unfortunately, a randomised trial directly comparing surgical and radiotherapy outcomes in this disease has not been completed.…”

mentioning

confidence: 99%